Posts Tagged: astrazeneca


Nasal Spray Patents Covering Migraine Drug Zomig Not Invalid As Obvious

The sole question on appeal was whether it would have been obvious to make zolmitriptan into a nasal spray. The Federal Circuit agreed with the district court …

FDA approval of Teflaro puts Allergan’s portfolio of anti-infectives into focus

Treatments for infectious diseases is one area where Allergan is looking to buoy its fortunes in the coming years. The first quarter of 2016 was a strong one …
By Steve Brachmann
3 years ago 0

Bristol-Myers, AstraZeneca and AmGen maintain strong new drug pipelines

There’s been a lot of positive activity in recent months for Bristol-Myers Squibb of New York City. In early March, the U.S. Food and Drug …
By Steve Brachmann
5 years ago 1

Biotech and Pharma Update: January 2014

Kava Plant May Prevent Cigarette Smoke-induced Lung Cancer *** Conditional Approval for Treatment of T-cell Lymphoma in Dogs *** All-Oral, Interferon-Free Therapy for the Treatment of Hepatitis C Genotype 1 *** …
By Gene Quinn
6 years ago 1

Biotech and Pharma Update: News for December 2013

What follows below is a review of some of the biotech and pharma news stories that caught my attention during the month of December 2013. Fitch Puts Negative …
By Gene Quinn
6 years ago 0

Patent Business: Deals, Acquisitions & Licenses Vol. 1

Merck and AstraZeneca Agree to Amend Partnership - Theradiag Acquires Innovative MicroRNA Technology Platform - 8x8 Sells Patent Family - MPEG LA Announces Call for Patents Essential …
By Gene Quinn
7 years ago 1

CAFC Rules “Secret Prior Art” Requires Only Appreciation that Invention Made in Teva Pharmaceutical*

The doctrines of “secret prior art” and “inherency” both merged in the case Teva Pharmaceutical Industries Ltd. v. AstraZeneca Pharmaceuticals LP to surprise, and unpleasantly upend the …
By Eric Guttag
8 years ago 10

Licensing Executives Society Announces 2010 Deals of Distinction™ Awards

In May 2009, Genzyme Corporation acquired the worldwide rights to a potential breakthrough treatment for Multiple Sclerosis (MS) along with three marketed oncology products from Bayer Healthcare Pharmaceuticals. …
By Gene Quinn
9 years ago 0

The Puzzling Difference Between Schmutz X and Compound 24028 in AstraZeneca

Determining what compounds are obvious under the doctrine of “structural similarity” can be a daunting challenge, even for those of us with a chemistry or pharmaceutical background.  …
By Eric Guttag
10 years ago 1

Dr. Reddy’s Wins Prilosec Summary Judgment

On Tuesday, March 10, 2009, Dr. Reddy’s Laboratories (NYSE:RDY) prevailed in a patent dispute with Astra Zeneca, receiving a summary judgment victory in the ongoing dispute before …
By Gene Quinn
11 years ago 0